Shilpa Medicare gets USFDA nod for cancer drug
Shares of Shilpa Medicare were trading 2.19 per cent up at Rs 359 apiece on the BSE25-02-2019
25-02-2019
Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- USFDA Approval Received.
This is to inform you that the Company has received U.S Food and Drug Administration approval for its ANDA, Gemcitabine for Injection USP, 200 mg/vial and 1 g/vial. Gemcitabine for Injection USP is a generic equivalent of reference listed drug (RLD), GEMZAR used in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer & pancreatic cancer as recommended in the label approved by FDA.' According to IQVIA MAT 12/2018, the US market for Gemcitabine for Injection USP, 200 mg/vial and 1 g/vial is approximately US$ 11.7 Million. This is for your information and doing the needful.25-02-2019
Shilpa Medicare Ltd - 530549 - FINANCIAL RESULTS FOR QUARTER ENDED 31/12/2018
THE BOARD OF DIRECTORS APPROVED FINANCIAL RESULTS FOR QUARTER ENDED 31/12/201807-02-2019
Shilpa Medicare Ltd - 530549 - Outcome of Board Meeting
THE BOARD OF DIRECTORS MEETING WAS HELD TO APPROVE THE UN AUDITED FINANCIALS FOR QUARTER ENDED 31-12-201807-02-2019
SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for BOARD MEETING INTIMATION UNDER REGULATION 29 OF SEBI (LODR) 2015
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2019 ,inter alia, to consider and approve We wish to inform you that a meeting of Board of Directors will be held on Thursday, the 07th day of February, 2019, inter alia to consider the Un-audited financial results for the third quarter ended 31st December, 2018 in compliance of Regulation 33 of the said regulations. As per code of conduct for prevention of Insider Trading, framed and adopted in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It is further intimated that Trading Window would remain closed from 01/02/2019 to 09/02/2019, both days inclusive, for the following categories (including dependents): Directors Designated Employees Auditors This is for your information and records.31-01-2019
SHILPA MEDICARE LTD. - 530549 - Shareholding for the Period Ended December 31, 2018
Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here22-01-2019
SHILPA MEDICARE LTD. - 530549 - Announcement Under Regulation 30 Of SEBI (LODR) 2015
This is to inform you that the Company has received U.S Food and Drug Administration approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg on 17.01.2019. Imatinib Mesylate Tablets is a generic equivalent of the reference listed drug (RLD), gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended in the label approved by FDA. According to IQVIA MAT Q2 2018 data, the US market for Imatinib Mesylate Tablets, 100 mg and 400 mg is approximately US$ 885 Million. This is for your information and doing the needful.18-01-2019
SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0990 Name of the Signatory :- MADHUSUDHAN REDDYDesignation :- Company Secretary and Compliance Officer16-01-2019
Shilpa Medicare Ltd - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Brijgopal Innani11-01-2019
Shilpa Medicare gets USFDA nod for cancer treatment injection
Shilpa Medicare on Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for the treatment of certain01-01-2019